Soleno Therapeutics/$SLNO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Ticker
$SLNO
Sector
Primary listing
Employees
152
Headquarters
Website
SLNO Metrics
BasicAdvanced
$2.6B
-
-$1.62
-3.19
-
Price and volume
Market cap
$2.6B
Beta
-3.19
52-week high
$90.32
52-week low
$41.50
Average daily volume
2M
Financial strength
Current ratio
16.084
Quick ratio
15.771
Long term debt to equity
10.502
Total debt to equity
10.643
Interest coverage (TTM)
-19.34%
Profitability
EBITDA (TTM)
-82.259
Gross margin (TTM)
98.14%
Net profit margin (TTM)
-79.50%
Operating margin (TTM)
-85.40%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
-11.75%
Return on equity (TTM)
-20.66%
Valuation
Price to revenue (TTM)
23.462
Price to book
5.18
Price to tangible book (TTM)
5.24
Price to free cash flow (TTM)
-89.319
Free cash flow yield (TTM)
-1.12%
Free cash flow per share (TTM)
-0.534
Growth
Earnings per share change (TTM)
-53.30%
10-year revenue growth (CAGR)
75.01%
3-year earnings per share growth (CAGR)
-17.74%
10-year earnings per share growth (CAGR)
-38.74%
Bulls say / Bears say
FDA approved VYKAT XR on March 26, 2025 as the first therapy for hyperphagia in Prader-Willi syndrome, marking a significant milestone for Soleno and the PWS community. (PharmExec)
On April 14, 2025, Soleno delivered the first prescriptions of VYKAT XR to patients with Prader-Willi syndrome, demonstrating an efficient commercial launch process. (GlobeNewswire)
Subsequent to the second quarter ended June 30, 2025, Soleno secured $230 million in gross proceeds from a common stock offering, strengthening its capital base for ongoing commercialization. (GlobeNewswire)
Soleno’s only approved product is VYKAT XR, and its pipeline beyond this lead candidate remains in early clinical or preclinical stages, leaving the company reliant on a single therapy for revenue generation. (SEC 10-K)
As of September 30, 2025, Soleno reported an accumulated deficit of $474.7 million and net losses of $22.5 million for the nine months ended, underscoring historical unprofitability. (SEC 10-Q)
The company’s sustained profitability is contingent upon ongoing successful commercialization of VYKAT XR in a niche Prader-Willi syndrome market, exposing growth prospects to limited patient-population dynamics. (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
SLNO News
AllArticlesVideos
SLNO INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Soleno Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
Business Wire3 days ago
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO
Business Wire2 weeks ago
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $2.6B as of November 14, 2025.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of November 14, 2025.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of November 14, 2025.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -3.19. This means that it has an inverse relation to market volatility.